Health Canada Grants Priority Review Status for Heron Therapeutics’ New Drug Submission for HTX-011 for Management of Postoperative Pain
- Tuesday, December 3, 2019, 7:41
- Environment
- Add a comment
SAN DIEGO, Dec. 3, 2019 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that…
About the Author
adminasapcorp has written 39353 stories on this site.